Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Convertible Debt (2016 - 2019)

Ani Pharmaceuticals (ANIP) has disclosed Convertible Debt for 9 consecutive years, with $117.6 million as the latest value for Q3 2019.

  • Quarterly Convertible Debt fell 12.33% to $117.6 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $117.6 million through Sep 2019, down 12.33% year-over-year, with the annual reading at $112.5 million for FY2018, 12.28% down from the prior year.
  • Convertible Debt hit $117.6 million in Q3 2019 for Ani Pharmaceuticals, up from $115.9 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $134.1 million in Q3 2018 to a low of $112.2 million in Q1 2015.
  • Historically, Convertible Debt has averaged $120.2 million across 5 years, with a median of $117.6 million in 2019.
  • Biggest five-year swings in Convertible Debt: grew 6.46% in 2015 and later decreased 12.33% in 2019.
  • Year by year, Convertible Debt stood at $113.4 million in 2015, then rose by 6.36% to $120.6 million in 2016, then grew by 6.27% to $128.2 million in 2017, then fell by 12.28% to $112.5 million in 2018, then grew by 4.56% to $117.6 million in 2019.
  • Business Quant data shows Convertible Debt for ANIP at $117.6 million in Q3 2019, $115.9 million in Q2 2019, and $114.2 million in Q1 2019.